Published in:
01-06-2006 | Editorial
Which radionuclides will nuclear oncology need tomorrow?
Authors:
Jacques Barbet, Jean-François Chatal, François Gauché, Jacques Martino
Published in:
European Journal of Nuclear Medicine and Molecular Imaging
|
Issue 6/2006
Login to get access
Excerpt
The role of nuclear medicine in oncology has changed dramatically in recent years owing to outstanding technical advances in imaging and therapy. This progress is opening up new, exciting perspectives which should ensure that nuclear medicine techniques will become standard diagnostic and therapeutic modalities, complementing conventional modalities. Positron emission tomography/computed tomography (PET/CT) technology with
18F-fluorodeoxyglucose (FDG), which has been developed clinically in less than 10 years, is now accepted as the gold standard in oncological imaging [
1]. Moreover, a number of other fluorinated radiopharmaceuticals are being evaluated for their ability to complement FDG [
2], and some could be approved for routine clinical use in the future. …